Insights into Growth Factors in Liver Carcinogenesis and Regeneration: An Ongoing Debate on Minimizing Cancer Recurrence after Liver Resection.

dc.contributor.authorÁlvarez-Mercado, Ana I
dc.contributor.authorCaballeria-Casals, Albert
dc.contributor.authorRojano-Alfonso, Carlos
dc.contributor.authorChávez-Reyes, Jesús
dc.contributor.authorMicó-Carnero, Marc
dc.contributor.authorSanchez-Gonzalez, Alfredo
dc.contributor.authorCasillas-Ramírez, Araní
dc.contributor.authorGracia-Sancho, Jordi
dc.contributor.authorPeralta, Carmen
dc.date.accessioned2025-01-07T17:05:43Z
dc.date.available2025-01-07T17:05:43Z
dc.date.issued2021-09-04
dc.description.abstractHepatocellular carcinoma has become a leading cause of cancer-associated mortality throughout the world, and is of great concern. Currently used chemotherapeutic drugs in the treatment of hepatocellular carcinoma lead to severe side effects, thus underscoring the need for further research to develop novel and safer therapies. Liver resection in cancer patients is routinely performed. After partial resection, liver regeneration is a perfectly calibrated response apparently sensed by the body's required liver function. This process hinges on the effect of several growth factors, among other molecules. However, dysregulation of growth factor signals also leads to growth signaling autonomy and tumor progression, so control of growth factor expression may prevent tumor progression. This review describes the role of some of the main growth factors whose dysregulation promotes liver tumor progression, and are also key in regenerating the remaining liver following resection. We herein summarize and discuss studies focused on partial hepatectomy and liver carcinogenesis, referring to hepatocyte growth factor, insulin-like growth factor, and epidermal growth factor, as well as their suitability as targets in the treatment of hepatocellular carcinoma. Finally, and given that drugs remain one of the mainstay treatment options in liver carcinogenesis, we have reviewed the current pharmacological approaches approved for clinical use or research targeting these factors.
dc.identifier.doi10.3390/biomedicines9091158
dc.identifier.issn2227-9059
dc.identifier.pmcPMC8470173
dc.identifier.pmid34572344
dc.identifier.pubmedURLhttps://pmc.ncbi.nlm.nih.gov/articles/PMC8470173/pdf
dc.identifier.unpaywallURLhttps://www.mdpi.com/2227-9059/9/9/1158/pdf?version=1631079633
dc.identifier.urihttps://hdl.handle.net/10668/28170
dc.issue.number9
dc.journal.titleBiomedicines
dc.journal.titleabbreviationBiomedicines
dc.language.isoen
dc.organizationInstituto de Investigación Biosanitaria de Granada (ibs.GRANADA)
dc.organizationSAS - Hospital Universitario San Cecilio
dc.organizationSAS - Hospital Universitario Virgen de las Nieves
dc.organizationSAS - Hospital Universitario San Cecilio
dc.organizationInstituto de Investigación Biosanitaria de Granada (ibs.GRANADA)
dc.pubmedtypeJournal Article
dc.pubmedtypeReview
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectepidermal growth factor
dc.subjectgrowth factors
dc.subjecthepatocyte growth factor
dc.subjectinsulin-like growth factor-1
dc.subjectliver cancer
dc.subjectliver resection
dc.subjectregeneration
dc.titleInsights into Growth Factors in Liver Carcinogenesis and Regeneration: An Ongoing Debate on Minimizing Cancer Recurrence after Liver Resection.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number9

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
PMC8470173.pdf
Size:
1.91 MB
Format:
Adobe Portable Document Format